Citius Oncology Presents Positive Quality of Life Data for LYMPHIR®
Citius Pharmaceuticals, Inc.'s subsidiary, Citius Oncology, Inc., announced positive health-related quality of life (HRQoL) results from its pivotal Study 302 of LYMPHIR® (denileukin diftitox-cxdl) in adults with relapsed or refractory cutaneous T-cell lymphoma. The data, presented at the EORTC-CLTG 2026 Annual Meeting, indicated that patients who responded to LYMPHIR experienced sustained improvements in skin-related quality of life measures, including significant reductions in itch for a notable portion of heavily pretreated patients. These findings underscore the importance of quality of life considerations in treatment decisions for CTCL.
Key Highlights
- Citius Oncology announced health-related quality of life (HRQoL) results from pivotal Study 302 of LYMPHIR® (denileukin diftitox-cxdl).
- Patients who responded to LYMPHIR reported sustained improvement in skin-related quality of life measures.
- Among responders (n=25), mean change from baseline in Skindex-29 Total Score ranged from -5.38 to -13.69 points.
- Among responders, FACT-G Total Score showed a sustained benefit at the end of treatment (+3.21 mean change from baseline).
- 32% (13/41) of heavily pretreated patients with significant itch noted a decrease of at least 20 mm sustained for four weeks or longer.
Price Impact
More from CTXR
Citius Oncology Presents Promising Phase 1 Data for LYMPHIR in Gynecologic Cancers
Citius Pharma Q2 Net Loss $(21.2)M; LYMPHIR Revenue $1.7M; Secures $41.5M Financing
Citius Pharma Q2 Net Loss $37.5M; $5.6M Revenue; Going Concern Doubt